Últimas noticias sobre Envoy Medical (NASDAQ:COCH) Bolsa

Envoy Medical

Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical Inc

Cochlear Ltd

<ul>
<li>PLTR</li>
<li>NVDA</li>
<li>TSLA</li>
<li>AMZN</li>
<li>AMD</li>
<li>SMCI</li>
<li>GOOGL</li>
<li>ELF</li>
<li>BABA</li>
<li>GOOG</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AMZN

BABA

GOOG

GOOGL

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of February 7, 2025 (Via Swaggy Stocks)

Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.43%. Currently, Automatic Data Processing has a market capitalization of $125.91 billion. 
Buying $1000 In ADP: If an investor had bought $1000 of ADP stock 20 years ago, it would be worth $7,261.34 today based on a price of $309.47 for ADP at the time of writing.
<h3>Automatic Data Processing's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738937783_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

$1000 Invested In Automatic Data Processing 20 Years Ago Would Be Worth This Much Today

Piper Sandler analyst Brian Mullan downgrades Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) from Overweight to Neutral and lowers the price target from $92 to $90.

Downgrades

Price Target

Analyst Ratings

PFGC

Piper Sandler Downgrades Performance Food Gr to Neutral, Lowers Price Target to $90

On Friday, Avantor Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)&nbsp;reported fourth-quarter net sales of&nbsp;$1.69 billion, a decrease of 2% year-over-year, missing <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $1.71 billion</a>.
Foreign currency translation and Clinical Services divestiture had a negative impact, resulting in sales growth of 1% <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43555469/avantor-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">on an organic basis</a>.
Net income increased to&nbsp;$500.4 million&nbsp;from&nbsp;$98.5 million&nbsp;a year ago, and adjusted net income was&nbsp;$183.9 million&nbsp;compared to&nbsp;$166.7 million&nbsp;in the comparable prior period.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42091430/nvidia-partners-with-quantum-si-to-advance-single-molecule-analysis" rel="noreferrer noopener">Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis</a>
The life science tools company reported the adjusted EBITDA was $307.7 million, and the margin was 18.2%. Adjusted operating income was $279.4, with a margin of 16.6%.
The company reported an adjusted EPS of 27 cents, up from 29 cents a year ago, beating the consensus of 26 cents.
Operating cash flow was&nbsp;$173.3 million, while free cash flow was&nbsp;$222.1 million.
&#8220;As anticipated, we returned to growth in the fourth quarter and delivered sequential and year-over-year growth in adjusted EBITDA margin, adjusted EPS, and best-in-class free cash flow conversion. We grew our bioprocessing platform high-single-digits and expect continued strength driven by our focused execution and improving end market conditions,&#8221; said&nbsp;Michael Stubblefield, President and Chief Executive Officer.
Laboratory Solutions&#8217; net sales were&nbsp;$1.13 billion, down 5%. Foreign currency translation and our Clinical Services divestiture had a negative impact, resulting in a 1% organic sales decline.
Bioscience Production net sales were&nbsp;$560.8 million, up 4%.&nbsp;Sales increased 4% organically.
Guidance:&nbsp;Avantor <a target="_blank" href="https://s202.q4cdn.com/498171784/files/doc_financials/2024/q4/Avantor_Q4-2024_Earnings-Presentation_vFINAL.pdf" rel="noreferrer noopener">expects</a> 2025 organic revenue growth of 1%-3% compared to 2024 decline of 2%, with adjusted EBITDA margin of 18%-19%
The company forecasts adjusted EPS of $1.02-$1.10 versus the consensus of $1.10 and expected free cash flow of $650 million—$700 million.
Price Action: AVTR stock is down 3.73% at $20.89 during the premarket session on last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43557307/wynns-al-marjan-island-resort-expansion-gains-momentum-secures-record-24-billion-loan" target="_blank" rel="noreferrer noopener">Wynn&#8217;s Al Marjan Island Resort Expansion Gains Momentum, Secures Financing</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

General

AVTR

Life Science Tools Firm Avantor Reports Mixed Q4 Earnings, Forecasts Organic Sales Growth In 2025

WIIM

NTRB

Nutriband shares are trading higher after the company announced a notice of allowance for a patent application.

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares rose slightly in premarket trading on Friday, following a positive update on its operations<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> during the Chinese New Year holiday.</a>
The company reportedly saw a significant surge in its battery swap services, driven by the travel rush during the holiday period from Jan. 28 to Feb. 4, <a href="https://cnevpost.com/2025/02/07/nio-record-battery-swaps-chinese-new-year-2025/" target="_blank" rel="noreferrer noopener">reports </a>CnEV Post.
On Feb. 3, the company recorded 136,720 battery swap services in a single day, marking a notable peak in demand.
This followed a strong performance on Jan. 25, with 119,848 services in one day, showcasing the growing popularity of NIO&#8217;s battery swap technology.
NIO also reported strong vehicle deliveries for January 2025, with a 37.9% year-over-year increase<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43418737/nio-inc-provides-january-2025-delivery-update" rel="noreferrer noopener">, totaling 13,863 units</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43555871/amazon-declines-3-in-friday-pre-market-whats-going-on" rel="noreferrer noopener">Amazon Declines Nearly 3% In Friday Pre-Market: What&#8217;s Going On?</a>
Of these, 7,951 vehicles came from its premium smart electric vehicle brand, NIO, while 5,912 were from its family-oriented ONVO brand.
As of Jan. 31, the company&#8217;s cumulative deliveries reached 685,427 units.
In addition to its operational performance, NIO is poised for inclusion in a major Hong Kong stock index, which is expected to attract passive investment inflows and <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43054613/whats-going-on-with-chinese-ev-maker-nio-stock-today" rel="noreferrer noopener">could provide a boost to the company&#8217;s stock price.</a>
The Hang Seng Indexes Company Limited will announce the results of its semi-annual review on February 21, with changes taking effect on March 10.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NIO stock has lost over 28% in the past year. Investors can gain exposure to the stock via&nbsp;KraneShares Electric Vehicles and Future Mobility Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KARS#NYSE">KARS</a>) and&nbsp;Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>).
Price Action: NIO shares are trading higher by 1.55% to $4.265 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/02/43491547/openais-sam-altman-looks-to-raise-funds-from-abu-dhabis-mgx-amid-increased-competition-report" target="_blank" rel="noreferrer noopener">OpenAI's Sam Altman Looks To Raise Funds From Abu Dhabi's MGX Amid Increased Competition: Report</a></li>
</ul>
Image: Shutterstock

Equities

Markets

KARS

PowerShares Golden Dragon Halter USX China Portfolio

What's Going On With NIO Stock Today? EV Maker Sees Surge In Battery Swap Services

Flowers Foods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>) reported a fourth-quarter sales decline of 1.6% year-on-year to $1.11 billion, missing the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43556480/flowers-foods-inc-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">consensus estimate of $1.13 billion</a>.
Adjusted EPS of $0.22 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the analyst consensus estimate of $0.21.</a>
Materials, supplies, labor, and other production costs were&nbsp;51.2%&nbsp;of net sales, a 90-basis point decrease.
Operating income for the quarter increased 22.9% to $61.4 million and the operating margin expanded 110 basis points to 5.5%.
Adjusted EBITDA increased 6.3% to&nbsp;$102.4 million with the margin expanding to 9.2%. Operating cash flow for the quarter totaled $130.3 million.
&#8220;Flowers&#8217; strong execution of our portfolio strategy and cost savings initiatives drove fourth quarter and full year 2024 adjusted EPS growth in a difficult economic environment,&#8221; said chairman and CEO Ryals McMullian.
&#8220;We expect continued strong execution as we navigate a difficult economic environment in 2025. First-half results are expected to benefit from the carryover of new business wins and savings and pricing initiatives, as well as moderating commodity costs.&#8221;
The company held $5.0 billion in cash and equivalents as of December 28, 2024.
Outlook: For FY25, Flowers expects revenue of $5.403 billion to $5.487 billion <a href="https://www.benzinga.com/calendars/guidance">versus the estimate of $5.22 billion.</a>
The company sees adjusted EPS of $1.11 to $1.24 against the consensus of $1.30. Capital expenditures are expected to be $140 million to $150 million.
Price Action: FLO shares are trading higher by 2.12% at $19.75 in premarket at the last check Friday.
Photo via Shutterstock.

Flowers Foods Posts Mixed Q4 Results, Warns Of Economic Uncertainty Ahead

WLDS

Wearable devices shares are trading higher after the company announced the introduction of large MUAP model AI-powered natural gesture technology.

The Kansas City Chiefs are attempting to win a third straight Super Bowl on Sunday with a matchup against the Philadelphia Eagles. While millions of NFL fans will tune in for the big game, millions will also tune in to see the <a href="https://www.benzinga.com/topic/super-bowl">Super Bowl commercials.</a>
What Happened: NFL media partner Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) has the rights to Super Bowl LIX and set its sights on charging $7 million for <a href="https://www.benzinga.com/general/sports/25/01/43324031/super-bowl-lix-commercials-hit-record-8-million-how-fox-corporation-can-win-from-nfl-championship">30-second commercial slots.</a>
The media company was able to secure the majority of its ad slots in the $7 million to $7.5 million range and some last-minute availability came with a price tag of $8 million. Fox also saw strong demand and price increases compared to last year for the pre-game and post-game slots.
While some companies are skeptical to advertise during the Super Bowl due to the high cost, last year's record viewership could lure major brands back, as the game remains one of the most-watched events in the U.S. annually.
Here is a look at the companies that are airing Super Bowl commercials in Super Bowl LIX, as <a href="https://adage.com/article/special-report-super-bowl/super-bowl-2025-commercials-ads-brands-and-agencies/2584221">reported </a>by AdAge.
Read Also: <a href="https://www.benzinga.com/general/sports/24/02/37076429/super-bowl-commercials-2024-complete-list-of-super-bowl-lviii-ads-and-companies-behind-them">Super Bowl Commercials 2024: Complete List Of Super Bowl LVIII Ads And Companies Behind Them</a>
The Public Companies: Here are the companies that are public or tied to a public company that are airing Super Bowl commercials. With strong reception, the ads could have an impact on the company's financials and likewise its stock.
<ul>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>): Disney+ streaming ad.</li>
<li>Totino's, brand of General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>): Pizza Rolls makes Super Bowl debut.</li>
<li>GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>): Focus on AI tool Airo with actor Walton Goggins.</li>
<li>Mountain Dew, unit of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): Musician Seal voices a seal.</li>
<li>Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>): Was first company to announce a Super Bowl ad way back in May, Chiefs head coach Andy Reid stars.</li>
<li>Stella Artois, brand of Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>): Brand's fourth Super Bowl ad and first since 2019, David Beckham meets his American twin Dave Beckham (Matt Damon).</li>
<li>Uber Eats, unit of Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>): Company's fifth straight year with a Super Bow ad, features Matthew McConaughey, Kevin Bacon, Sean Evans, Martha Stewart, Greta Gerwig and Charli XCX.</li>
<li>Coffee mate, brand of Nestle (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGY#OTC">NSRGY</a>): Coffee creamer makes Super Bowl debut.</li>
<li>Dove, brand of Unilever (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>): Brand's second straight Super Bowl ad.</li>
<li>Lay's, brand of PepsiCo: Ad for the All-dressed flavor that combines multiple flavors, Lay's first Super Bowl ad in three years.</li>
<li>DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>): Focus on DashPass subscriptions with comedian Nate Bargatze.</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): Tech giant returns for first time since 2022 with a focus on its Ray-Ban glasses featuring actors Chris Hemsworth and Chris Pratt.</li>
<li>Pringles, brand of Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>): Eighth consecutive Super Bowl ad from snack brand features actor Adam Brody along with the mustaches of Nick Offerman, James Harden and Andy Reid.</li>
<li>Coors Light, brand of Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>): Brand's third straight year with Super Bowl ad, centers on campaign of "Case of the Mondays" for the day after Super Bowl.</li>
<li>Doritos, brand of PepsiCo: Snack brand features a fan-made ad that won a contest.</li>
<li>Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>): Two Super Bowl ads will feature Matthew McConaughey and Woody Harrelson with a focus on AI.</li>
<li>Booking.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>): Travel company back for a fourth straight Super Bowl and features Muppets Miss Piggy, Kermit the Frog and Animal.</li>
<li>Bud Light, brand of Anheuser-Busch InBev: Cul-de-sac party featuring Bud Lights with comedian Shane Gillis, musician Post Malone and NFL great Peyton Manning.</li>
<li>Ram, brand of Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>): Automotive company is back with an ad for its truck with actor Glen Powell.</li>
<li>Reese's, brand of The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>): Focus on the Chocolate Lava Big Cup.</li>
<li>Google, brand of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): No details on the spot.</li>
<li>Instacart, brand of Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>): Delivery company makes Super Bowl debut, features mascots of iconic packaged goods companies.</li>
<li>TurboTax, brand of Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>): Company's 12th consecutive Super Bowl ad, promotes expert-assisted tax filing business.</li>
<li>Hellmann's, brand of Unilever: Likely one of the most talked about ads, Billy Crystal and Meg Ryan reunite at Katz's Delicatessen in New York to create a famous scene from "When Harry Met Sally."</li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>): Super Bowl debut, focus on the company's GLP-1 weight loss treatments.</li>
<li>Michelob Ultra, brand of Anheuser-Busch InBev: Actors William Dafoe and Catherine O'Hara hustle people playing pickleball.</li>
<li>Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>): Pharmaceutical giant makes Super Bowl debut with a 60-second ad on breast cancer.</li>
<li>Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>): Fintech returns to Super Bowl for first time since 2022.</li>
<li>Tubi, brand of Fox Corporation: Streaming platform will be featured in several spots as Fox promotes one of its own products.</li>
<li>Budweiser, brand of Anheuser-Busch InBev: Beer company planned a spot with the famous Clydesdale horses as a regional ad, but bumped up to a national spot after strong reception.</li>
<li>Homes.com, brand of CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>): Real estate company features celebrities in multiple Super Bowl ads.</li>
<li>Taco Bell, brand of Yum! Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>): First Super Bowl ad for restaurant brand in three years, features photos of real customers from drive-thru cameras.</li>
<li>Duracell, brand of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>): Battery company makes Super Bowl debut with commercial featuring "The Duracell Scientist" showing people's bad battery decisions.</li>
<li>FanDuel, brand of Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>): Sports betting company features Peyton Manning and Eli Manning in its now annual celebrity field goal kick during the Super Bowl.</li>
<li>Ritz, brand of Mondelez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>): Super Bowl debut.</li>
</ul>
The Private Companies: Here are the private companies that are airing Super Bowl commercials.
<ul>
<li>NerdWallet: Company's first Super Bowl ad, beluga whale mascot voiced by actor Kieran Culkin.</li>
<li>WeatherTech: Company's 13th Super Bowl ad in 12 years, comes after sitting last year's game out.</li>
<li>NFL: The National Football League will have several commercials in the game.</li>
<li>Come Near: "He Gets Us" religious ads as in past Super Bowls.</li>
<li>Little Caesars: First Super Bowl ad since 2020 and comes as the new official pizza of the NFL, Eugene Levy stars.</li>
<li>Nerds: Candy brand is back for a second-straight year with singer Shaboozey.</li>
<li>Squarespace: Former public website building company is back for 11th Super Bowl ad with actor Barry Keoghan.</li>
<li>Foundation to Combat Antisemitism: Patriots owner Robert Kraft is back with his foundation featuring Tom Brady and Snoop Dogg.</li>
<li>Dunkin': Coffee and donut company is back with Ben Affleck.</li>
<li>Häagen-Dazs: Ice cream brand's first ever Super Bowl ad features Vin Diesel, Michelle Rodriguez and Ludacris, all from the "Fast and Furious" franchise.</li>
<li>Poppi: Small soda makes second straight Super Bowl ad appearance with new "Soda Thoughts" campaign.</li>
<li>HexClad: Cookware company makes Super Bowl debut with actor Pete Davidson and celebrity chef Gordon Ramsay, who is a part owner of the company.</li>
<li>Bosch: German company makes Super Bowl debut.</li>
<li>Angel Soft, brand of Georgia-Pacific: Toilet paper brand makes Super Bowl debut.</li>
<li>Liquid Death: Water in a can company makes Super Bowl debut.</li>
<li>Cirkul: Water bottle brand makes Super Bowl debut.</li>
<li>Fetch: Company that rewards shoppers makes Super Bowl debut with a $1.2 million giveaway.</li>
<li>MSC Cruises: European cruise company's Super Bowl debut featuring actors Drew Barrymore and Orlando Bloom.</li>
<li>OpenAI: AI company to make Super Bowl debut, as <a href="https://www.wsj.com/tech/ai/openai-set-to-make-super-bowl-ad-debut-8fa1aff5">reported </a>by the Wall Street Journal Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/02/43542456/14-dot-com-companies-had-super-bowl-commercials-in-2000-heres-how-many-still-exist-today">14 Dot-Com Companies Had Super Bowl Commercials In 2000, Here&#8217;s How Many Still Exist Today</a></li>
</ul>
Photo: kovop/Shutterstock.com

Sports

BKNG

CART

CSGP

DASH

FLUT

FOXA

GDDY

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INTU

MDLZ

NSRGY

STLA

UBER

Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight

PROP

Prairie Operating shares are trading lower after the company announced a public offering of $200 million shares.

In an effort to bring South Korea's defense sector into the U.S. investment scene, Exchange Traded Concepts launched the Hanwha Asset Management's PLUS Korea Defense Industry Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KDEF#NYSE">KDEF</a>), offering investors <a href="https://www.benzinga.com/etfs">exposure to South Korea's thriving defense industry</a>.
"We are enthusiastic to introduce the PLUS Korea Defense Industry Index ETF (KDEF) to the U.S. market," said Hanwha CEO Kim Jong-ho. "Expanding on the foundation of our Plus K-Defense ETF listed in Korea, this launch represents an opportunity to provide U.S. investors with exposure to Korea's defense industry. We appreciate the support of Exchange Traded Concepts in bringing this ETF to the NYSE Arca."
KDEF aims to mirror the total return performance of the Korea Defense Industry Index. The fund comes with a net expense ratio of 0.65%, which is competitive.
Also Read: <a href="https://www.benzinga.com/25/02/43542002/calamos-new-cpsf-etf-offers-growth-with-a-safety-net">Calamos&#8217; New CPSF ETF Offers Growth With A Safety Net</a>
The Korea Defense Industry Index focuses on South Korean companies engaged in defense-related operations. This includes firms specializing in shipbuilding, satellite telecommunications, civil engineering and utility system construction, among other sectors. The new ETF aims to take advantage of this exposure.
To be included in the index, companies must have a minimum market capitalization of at least 300 billion Korean Won—approximately $206 million in U.S. dollars as of February 5, 2025. No single constituent holding is allowed to exceed 20% of the index's overall weighting. KDEF follows the index closely, with at least 80% of its investments allocated to securities within the Korea Defense Industry Index. 
Stability and impressive growth rates make South Korea a key market of interest and the safest route to invest in South Korean securities is through ETFs. Other popular ETFs with exposure to South Korean sectors are Franklin FTSE South Korea ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLKR#NYSE">FLKR</a>) and iShares MSCI South Korea ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWY#NYSE">EWY</a>), both of which have gained about 8% year-to-date.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/reit/25/02/43545630/reit-winners-and-losers-januarys-trends-reshaping-2025">REIT Winners And Losers: January&#8217;s Trends Reshaping 2025</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

FLKR

KDEF

South Korea's Defense Sector Gets A US Gateway With KDEF ETF

TNXP

Tonix Pharmaceutical shares are trading higher after the company provided preliminary Q4 financial results.

Editor&#8217;s note: This story has been updated with additional details.
U.S. employment growth lost steam in January, with job growth coming in well below expectations and marking a significant slowdown <a href="https://www.benzinga.com/news/econ-s">from the previous month. </a>
Nonfarm payrolls rose by 143,000 in January 2025, marking a sharp slowdown from the upwardly revised 307,000 in December and missing economist expectations of 170,000, as tracked by TradingEconomics.
The softer-than-expected data hints at a gradual cooling in hiring momentum. The official jobs report also reveals a weaker-than-expected unemployment rate and hotter-than-expected wage growth, indicating mixed signals about the health of the U.S. labor market.
&#8220;In January, job gains occurred in health care, retail trade, and social assistance. Employment declined in the mining, quarrying, and oil and gas extraction industry,&#8221; the Bureau of Labor Statistics stated.
November&#8217;s total nonfarm payroll employment was revised higher by 49,000, increasing from 212,000 to 261,000, while December&#8217;s figure rose by 51,000, from 256,000 to 307,000.
Despite the weaker hiring pace, the unemployment rate surprisingly inched down from 4.1% to 4% in January, beating expectations of a stable reading.
Average hourly earnings, a key measure of wage inflation, spiked 0.5% month-over-month, topping expectations of 0.3% and marking the highest increase since January 2024. On an annual basis, wages increased 4.1%, up from 3.9% previously, and beating estimates of 3.8%. 
Beyond the headline numbers, Friday&#8217;s job market report also included the annual benchmark revision to the establishment survey and updated population controls in the household survey. 
The total nonfarm employment gain for the year ending March 2024 was revised down from 2,900,000 to 2,346,000.
<h3 class="wp-block-heading">Market Reaction</h3>
Financial markets showed little reactions to the jobs report, with U.S. equity futures holding flat as investors reassessed the Fed's policy outlook. 
The U.S. dollar index, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), inched up by 0.2%, driven by rising Treasury yields.
The yield on the 10-year Treasury note was up by 5 basis points to 4.49% by 9 a.m. ET Friday. Yields on both longer- and shorter-dated maturities rose in a similar fashion. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) was 0.6% lower in premarket trading.
Gold, which is tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), held steady at $2,865 per ounce, hovering at record highs. 
Sector-wise, communication services outperformed, up 0.5%, while consumer discretionary stocks lagged, down 0.6%.
On Thursday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed 0.4% higher.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43544975/banks-win-first-regulatory-relief-as-fed-softens-stress-test-rules-scraps-climate-risks-financial-stocks-hit-record-highs">Fed Eases Bank Stress Tests, Drops Climate Risks: Financial Stocks Hit Record Highs</a></li>
</ul>
Photo via Shutterstock.

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

US Economy Adds Fewer Than Expected Jobs In January, Unemployment Rate Slows, Wage Growth Spikes (UPDATED)

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

Perella Weinberg shares are trading higher after the company reported better-than-expected Q4 financial results.

As part of this transformation, the Company has conducted a comprehensive, organization-wide analysis to determine the appropriate team size and structure. Following this review, the Company has completed a headcount restructuring process aimed at streamlining operations and reducing costs. This includes a 20% reduction in workforce across the Company to create operational efficiencies and align resources to support our technology-driven objectives. CFO Don Quinby noted, "Workforce reductions are always difficult and never a decision we make lightly. We are making every effort to treat our departing colleagues with respect and gratitude for their contributions and support them in their transition. These measures are expected to strengthen Fr8Tech's financial results over 2025 and better position the Company to reach profitability on an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) basis by the end of the year."

Management

FRGT

Fr8Tech Announces 20% Workforce Reduction To Streamline Operations And Reduce Costs; Aims For Profitability On Adjusted EBITDA Basis By End Of 2025

Wedbush analyst Nick Setyan upgrades Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) from Neutral to Outperform and raises the price target from $6 to $10.

Upgrades

Wedbush Upgrades Spectrum Brands Holdings to Outperform, Raises Price Target to $10

CLFD

Clearfield shares are trading lower after the company reported worse-than-expected Q1 sales results.

Fortive Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) shares are trading lower after the company&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43557376/fortive-reports-strong-fourth-quarter-and-full-year-2024-results-introduces-first-quarter-and-full" rel="noreferrer noopener">reported&nbsp;fourth-quarter&nbsp;results</a>.
Revenue grew&nbsp;2% year-over-year (Y/Y) to $1.620 billion,&nbsp;missing the consensus of&nbsp;$1.624 billion.
Core Growth Sales by segments: Intelligent Operating Solutions $710.8 million (+<a href="https://d1io3yog0oux5.cloudfront.net/_b6473ba34b04e3c63d57920de052a56b/fortive/db/924/11185/pdf/FTV-4Q-2024-Earnings-Presentation.pdf" target="_blank" rel="noreferrer noopener">4.1</a>% Y/Y), Precision Technologies $567.7 million (-0.4% Y/Y) and Advanced Healthcare Solutions $341.8 million (+3.2% Y/Y).
The company&#8217;s adjusted operating margin is up 100 basis points Y/Y to 28.7% in the quarter. Adjusted EPS of $1.17, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beating the consensus of $1.12</a>. It also reported an operating cash flow of $502 million and a free cash flow of $465 million in the quarter.
&#8220;Continued growth in our Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) segments was driven by steady demand for our safety and productivity solutions and increased contributions from FBS-driven product innovations,&#8221; said James A. Lico, president and CEO.
&#8221;We saw strong order growth across all of our segments, including the second consecutive quarter of double-digit orders growth for our Precision Technologies (PT) segment. This momentum drove sequential improvement in PT core growth and supports our view of a gradual recovery as we move through 2025.&#8221;
Outlook:&nbsp;For FY25, Fortive expects revenue of $6.23&nbsp;billion&nbsp;–&nbsp;$6.35&nbsp;billion&nbsp;versus a consensus of&nbsp;$6.488 billion and adjusted EPS&nbsp;of&nbsp;$4.00&nbsp;–&nbsp;$4.12&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">versus the consensus of&nbsp;$3.85</a>.
For the&nbsp;first quarter&nbsp;of FY25, Fortive anticipates revenue of&nbsp;$1.48 billion –$1.51 billion&nbsp;(consensus:&nbsp;$1.565 billion) and adjusted EPS of&nbsp;$0.83 –&nbsp;$0.86 (consensus&nbsp;$0.91).
Investors can gain exposure to the stock via&nbsp;Themes Natural Monopoly ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZAR#NASDAQ">CZAR</a>) and Themes Robotics &amp; Automation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTT#NASDAQ">BOTT</a>).
Price Action:&nbsp;FTV shares are down 3.57% at $76.99 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43335937/palo-alto-taiwan-semiconductor-fortive-and-a-major-financial-stock-on-cnbcs-final-trades" target="_blank" rel="noreferrer noopener">Palo Alto, Taiwan Semiconductor, Fortive And A Major Financial Stock On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo: Shutterstock

Large Cap

BOTT

CZAR

Fortive Q4: EPS Tops, Revenue Misses, CEO Confident In 2025 Recovery

DENN

Denny's shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform and raised its price target from $6 to $10.

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
78% of subjects maintained a clinically meaningful benefit of more than 3 points in rVCSS at 24 months, with an average improvement of 8.2 points among the responder cohort.
Subjects continued to experience a median 75% reduction in pain at 24 months.
Interim follow-up data indicate sustained improvements across all venous specific quality-of-life(QoL) indicators.
PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025.
IRVINE, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / February 7, 2025 / enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that interim two-year follow-up data on 34 subjects from the VenoValve U.S. pivotal trial will be presented today by Dr. Matthew Smeds, Professor of Surgery in the Division of Vascular and Endovascular Surgery at Saint Louis University and Principal Investigator for the trial, at the <a href="https://pr.report/6xb2">Vascular and Endovascular Surgery Society (VESS) 2025 Annual Winter Meeting</a>, being held February 6-9, 2025 in Breckenridge, CO. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), and the review process is ongoing, with a decision anticipated in the second half of 2025.
Key interim two-year follow-up data being presented at VESS includes:
78% of subjects (n=25/32) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).
Among the responder cohort, the average rVCSS improvement increased from 6.6 points at 12 months to 8.2 points at 24 months, demonstrating increasing benefit over time.
At 24 months, subjects continued to experience a median 75% reduction in pain, as measured by the Visual Analog Scale (VAS).
Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym) from 12 months to 24 months.
Among the subjects with core lab-evaluable data at 24 months, a 100% device patency rate was observed in all 27 subjects.
The rVCSS is a clinically validated scoring system used to track the progression or regression of venous diseases. The FDA previously indicated that an improvement of 3 or more points in rVCSS would be evidence of the VenoValve's clinical benefit.

Biotech

NVNO

enVVeno Medical Announces Hancock Jaffe's VenoValve Trial Shows 75% Pain Reduction at 24 Months; 78% Of Patients Maintain Over 3-Point Improvement In rVCSS At 24 Months; FDA Decision Anticipated In H2 2025

Lake Street analyst Frank Takkinen maintained a Buy rating on Envoy Medical (COCH – Research Report) today and set a price target of $6.00. The com...

Envoy Medical (COCH) Receives a Buy from Lake Street

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report) and...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Envoy Medical (COCH) announces that its Investigational Device Exemption, IDE, application for its pivotal study of the Acclaim Fully Implanted Coc...

Envoy Medical receives FDA approval to initiate study for hearing device

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Butterfly Network (BFLY – Research Report) and Envoy...

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Envoy Medical (COCH)

Envoy Medical (COCH) announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential b...

Envoy Medical announces publication on Acclaim CI

Reports Q3 revenue $56,000 vs. $80,000 last year. "The progress and accomplishments of late have been extremely important to Envoy Medical (COCH) a...

Envoy Medical reports Q3 EPS (37c) vs. 13c last year.

Envoy Medical GAAP EPS of -$0.37 misses by $0.11, revenue of $0.05M misses by $0.02M

Lake Street analyst Frank Takkinen reiterated a Buy rating on Envoy Medical (COCH – Research Report) today and set a price target of $6.00. The com...

Lake Street Sticks to Their Buy Rating for Envoy Medical (COCH)

Envoy Medical (COCH) announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on Novemb...

Envoy Medical announces four new patents

In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on Envoy Medical (COCH – Research Report), with a price target ...

Lake Street Keeps Their Buy Rating on Envoy Medical (COCH)

ARQT

BFLY

COCH

Press Releases

Envoy Medical Celebrates First Anniversary Trading as a Public Company under COCH on Nasdaq Capital Market

American Medical Association Approves Groundbreaking New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Opening New Opportunities for Envoy Medical's Esteem® Device

Comments

Envoy Medical

Noticias

Últimas noticias sobre Envoy Medical (NASDAQ:COCH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL